

Ref: *SSN/18-19/05*  
The Board of Directors  
Bayer CropScience Limited,  
Bayer House, Central Avenue  
Hiranandani Estate  
Thane 400 607

**Independent Auditor's Certificate certifying the accounting treatment contained in the Draft Scheme of Amalgamation of Monsanto India Limited with Bayer CropScience Limited and their respective shareholders**

1. This certificate is issued in accordance with the terms of our engagement letter dated October 23, 2018.
2. We, Deloitte Haskins & Sells LLP, Chartered Accountants, the Statutory Auditors of Bayer CropScience Limited ("the Company" or "the Transferee Company"), have examined the proposed accounting treatment specified in Clause 8 'Accounting treatment in the books of the Transferee Company' of Part IV, of the Draft Scheme of Amalgamation of 'Monsanto India Limited' ("the Transferor Company") with Bayer CropScience Limited and their respective shareholders ("the Draft Scheme") in terms of the provisions of Sections 230 to 232 of the Companies Act, 2013 with reference to its compliance with the applicable Accounting Standards notified under Section 133 of the Companies Act, 2013, read with the rules made there under and other generally accepted accounting principles.

**Management's responsibility**

3. The responsibility for the preparation of the Draft Scheme and its compliance with the relevant laws and regulations, including the applicable Accounting Standards read with the rules made there under and other generally accepted accounting principles as aforesaid, is that of the Board of Directors of the Companies involved. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the Draft Scheme and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.



**Deloitte  
Haskins & Sells LLP**

**Auditor's responsibility**

- 4. Our responsibility is only to examine and report whether the accounting treatment referred to in Clause 8 of part IV of the Draft Scheme referred to above complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and circulars issued there under and the applicable Accounting Standards notified under Section 133 of the Companies Act, 2013, read with the rules made there under, and Other Generally Accepted Accounting Principles. Nothing contained in this Certificate, nor anything said or done in the course of, or in connection with the services that are subject to this Certificate, will extend any duty of care that we may have in our capacity as the statutory auditors of any financial statements of the Transferee Company.
  
- 5. We carried out our examination in accordance with the Guidance Note on Reports or Certificates for Special Purposes, issued by the Institute of Chartered Accountants of India (ICAI) and Standards on Auditing specified under Section 143(10) of the Companies Act, 2013, in so far as applicable for the purpose of this certificate. This Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by ICAI.
  
- 6. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements. Further our examination did not extend to any other parts and aspects of a legal or proprietary nature in the aforesaid Draft Scheme.

**Opinion**

- 7. Based on our examination and according to the information and explanations given to us, we are of the opinion that the proposed accounting treatment in the books of the Transferee Company contained in Clause 8 of part IV of the Draft Scheme, is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and circulars issued there under, in terms of the provisions of Sections 230 to 232 of the Companies Act, 2013 with reference to its compliance with the applicable Accounting Standards notified under Section 133 of the Companies Act, 2013, read with the rules made there under, and Other Generally Accepted Accounting Principles, as applicable.
  
- 8. For ease of references, Clause 8 of part IV of the Draft Scheme, duly authenticated on behalf of the Transferee Company, is reproduced in Annexure 1 to this Certificate and is initialed by us only for the purposes of identification.



**Deloitte  
Haskins & Sells LLP**

**Restriction on use**

9. This certificate is issued at the request of the Company pursuant to the requirements of circulars issued under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as well as the provisions of Section 230 to 232 of the Companies Act, 2013 for onward submission by the Company to the Bombay Stock Exchange (BSE) and the National Company Law Tribunal. This Certificate should not be used for any other purpose without our prior written consent. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this certificate is shown or into whose hands it may come without our prior consent in writing.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Sampada S Narvankar  
(Partner)  
(Membership No. 102911)

Place: Mumbai  
Date: November 12, 2018





Annexure 1

Relevant extract of the Draft Scheme of Amalgamation of 'Monsanto India Limited' ("the Transferor Company") with Bayer CropScience Limited and their respective shareholders ("the Draft Scheme") in terms of the provisions of Sections 230 to 232 of the Companies Act, 2013

ACCOUNTING TREATMENT

8.1 Upon the Scheme becoming effective the Transferee Company shall account for the amalgamation of the Transferor Company in its books of accounts in accordance with 'Pooling of Interest Method' of accounting as laid down in Appendix-C of IND-AS 103 (Business Combinations of entities under common control) as under:

8.1.1 All the assets and liabilities in the books of the Transferor Company shall be recorded by the Transferee Company in its books of accounts at their respective carrying amounts, as appearing in the books of the Transferor Company. No adjustment shall be made to reflect fair values, or recognise any new assets or liabilities.

8.1.2 The identity of the reserves shall be preserved and shall appear in the financial statements of the Transferee Company in the same form, in which they appeared in the financial statements of the Transferor Company.

8.1.3 The carrying amount of investments in the equity shares of the Transferor Company to the extent held by the Transferee Company, shall stand cancelled pursuant to Clause 6 of this Scheme and there shall be no further obligation in that behalf.

8.1.4 The excess of (a) the face value of the new shares issued and allotted plus any additional consideration in the form of cash pursuant to clause 5.1; and (b) the carrying amount of investments cancelled pursuant to Clause 8.1.3 over the net value of assets, liabilities and reserves of the Transferor Company acquired and recorded by the Transferee Company in terms of Clause 8.1.1 shall be transferred to Revenue Reserves (General Reserve and/ or Retained earnings).

8.1.5 Inter-company transactions and balances including loans, advances, amount receivable or payable inter-se between the Transferor Company and the Transferee Company as appearing in their books of accounts, if any, shall stand cancelled.

//////////  
Bayer CropScience Ltd.  
CIN: L24210MH1958PLC011173  
  
Registered and Corporate Office:  
Bayer House  
Central Avenue  
Hiranandani Estate  
Thane (West) – 400 607  
Maharashtra, India  
  
Tel : +91 22 2531 1234  
  
www.bayer.in  
www.cropscience.bayer.com

022





8.2 In case of any differences in the accounting policies between the Transferor Company and the Transferee Company, the impact of the same will be quantified and adjusted in the Revenue Reserves (General Reserve and/ or Retained earnings) of the Transferee Company to ensure that the financial statements of the Transferee Company reflect the true financial position on the basis of consistent accounting policies.

8.3 On the Scheme becoming effective, the financial statements of the Transferee Company (including comparative period presented in the financial statements of Transferee Company, if required) shall be restated for the accounting impact of amalgamation, as stated above, as if the amalgamation had occurred from the acquisition date (date when common control was established) or beginning of the said comparative period; whichever is later.

For and on behalf of Bayer CropScience Limited

A handwritten signature in black ink, appearing to read "U. Stefer".

Ulrich Stefer  
Executive Director and Chief Financial Officer

als

November 12, 2018

